Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens

Antonia Martinetti, Rosalba Miceli, Elisa Sottotetti, Maria Di Bartolomeo, Filippo de Braud, Arpine Gevorgyan, Katia Fiorella Dotti, Emilio Bajetta, Manuela Campiglio, Francesca Bianchi, Giacomo Bregni, Filippo Pietrantonio

Research output: Contribution to journalArticle

Abstract

The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imperative. The aim of this study was to investigate the prognostic role of circulating VEGF, PDGF, SDF-1, osteopontin and CEA in patients randomly assigned to three bevacizumab-based regimens. Plasma samples from 50 patients treated at a single Institution were analysed using the multiplex assay BioPlex™ 2200 (Bio-Rad Laboratories, Inc, Berkeley, CA, USA) at baseline, before first three cycles and subsequently every three cycles until disease progression. Prognostic analyses of baseline values were performed using multivariable Cox models, including disease extension >10 cm or ≤10 cm (measured as the sum of the diameters for all target lesions) as adjustment factor. The association between progression-free and overall survival and biomarkers modulation during treatment was studied using multivariable Cox models, which included summary statistics synthesizing during-treatment modulation together with disease extension. The biomarkers significantly associated with disease extension were baseline CEA (p = 0.012) and SDF-1 (p = 0.030). High values of VEGF and SDF-1 tended to be associated with worse prognosis, especially in terms of overall survival. The negative prognostic trend was more marked for baseline CEA as compared to other biomarkers; increasing values during treatment was significantly related to worse prognosis independently of disease extension (p = 0.007 and 0.016 for progression-free and overall survival, respectively). VEGF is related to bevacizumab pharmacodynamics and is associated to other angiogenic cytokines; some of the proposed biomarkers such as SDF-1 and CEA should be further validated for prognosis assessment and monitoring of bevacizumab-based treatment of advanced colorectal cancer.

Original languageEnglish
Pages (from-to)1753-1768
Number of pages16
JournalCancers
Volume6
Issue number3
DOIs
Publication statusPublished - Aug 29 2014

    Fingerprint

Keywords

  • Angiogenesis
  • Bevacizumab
  • Biomarkers
  • CEA
  • Colorectal cancer
  • SDF-1
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Martinetti, A., Miceli, R., Sottotetti, E., Di Bartolomeo, M., de Braud, F., Gevorgyan, A., Dotti, K. F., Bajetta, E., Campiglio, M., Bianchi, F., Bregni, G., & Pietrantonio, F. (2014). Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. Cancers, 6(3), 1753-1768. https://doi.org/10.3390/cancers6031753